{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:34:57Z","timestamp":1792715697683,"version":"4.5.0"},"reference-count":75,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,6,1]],"date-time":"2005-06-01T00:00:00Z","timestamp":1117584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2005,6]]},"DOI":"10.1016\/j.radonc.2005.03.003","type":"journal-article","created":{"date-parts":[[2005,5,12]],"date-time":"2005-05-12T07:44:59Z","timestamp":1115883899000},"page":"258.E1-258.E13","source":"Crossref","is-referenced-by-count":141,"title":["Radiopharmaceuticals for the palliation of painful bone metastases\u2014a systematic review"],"prefix":"10.1016","volume":"75","author":[{"given":"Glenn","family":"Bauman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Therapeutic Radiopharmaceutical Guidelines Group of Cancer Care Ontario's Program in Evidence-based Care","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manya","family":"Charette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Reid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinka","family":"Sathya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2005.03.003_bib1","first-page":"123","article-title":"Samarium-153-EDTMP in bone metastases","volume":"38","author":"Ahonen","year":"1994","journal-title":"J Nucl Biol Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib2","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1002\/cncr.10437","article-title":"A multiinstitutional, concurrent chemoradiation trial of strontium-89, estramustine, and vinblastine for hormone refractory prostate carcinoma involving bone","volume":"94","author":"Akerley","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.radonc.2005.03.003_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-8140(97)01912-9","article-title":"Dose response relationship and multiple dose efficacy and toxicity of samarium-153-EDTMP in metastatic cancer to bone","volume":"43","author":"Alberts","year":"1997","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib4","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000011881","article-title":"Strontium-89 chloride in the treatment of bone metastases from breast cancer","volume":"55","author":"Baziotis","year":"1998","journal-title":"Oncology"},{"key":"10.1016\/j.radonc.2005.03.003_bib5","first-page":"59a","article-title":"Repeated administration of strontium-89 for palliation of painful osseous metastases [abstract]","volume":"16","author":"Ben Josef","year":"1997","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib6","first-page":"511","article-title":"Strontium-89 chloride in the palliation of bone pain from metastatic cancer [abstract]","volume":"14","author":"Blitzer","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib7","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1200\/JCO.1995.13.2.502","article-title":"The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation","volume":"13","author":"Browman","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib8","first-page":"79","article-title":"Use of strontium-89 in endocrine-refractory prostate cancer metastatic to bone. Provincial genitourinary cancer disease site group","volume":"2","author":"Brundage","year":"1998","journal-title":"Cancer Prev Control"},{"key":"10.1016\/j.radonc.2005.03.003_bib9","first-page":"349","article-title":"Results of a double blind study of 89-strontium therapy of skeletal metastases of prostatic carcinoma","volume":"14","author":"Buchali","year":"1988","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib10","first-page":"S44","article-title":"Five-years of clinical experience with Sr-89 [abstract]","volume":"21","author":"Carretta","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000050349","article-title":"Treatment of metastatic bone pain with rhenium-188 hydroxyethylidene diphosphonate","volume":"10","author":"Chen","year":"2001","journal-title":"Med Principles Pract"},{"key":"10.1016\/j.radonc.2005.03.003_bib12","first-page":"1839","article-title":"Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I\/II trial","volume":"34","author":"Collins","year":"1993","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib13","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1007\/s002590100533","article-title":"A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer","volume":"28","author":"Dafermou","year":"2001","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib14","first-page":"1423","article-title":"Evaluation of thrombocytopenia in patients treated with rhenium-186-HEDP: guidelines for individual dosage recommendations","volume":"35","author":"De Klerk","year":"1994","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib15","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1007\/BF00181067","article-title":"Dose escalation study of rhenium-186 hydroxyethylidene diphosphonate in patients with metastatic prostate cancer","volume":"21","author":"De Klerk","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0936-6555(05)80975-6","article-title":"Palliation of bone metastases in prostate cancer. Hemibody irradiation or strontium-89?","volume":"4","author":"Dearnaley","year":"1992","journal-title":"Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib17","first-page":"251P","article-title":"The effect of 153-Sm-EDTMP on moderate and severe bone cancer pain [abstract]","volume":"38","author":"Deng","year":"1997","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib18","first-page":"57b","article-title":"Double blind, dose ranging study of strontium-89 chloride (89SrCl2) in bone metastases associated with breast cancer [abstract]","volume":"20","author":"Dodwell","year":"2001","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1097\/00003072-199307000-00026","article-title":"Strontium-89 chloride for pain palliation in the skeletal metastases of breast cancer [abstract]","volume":"18","author":"Dusing","year":"1993","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib20","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1097\/00006231-200007000-00004","article-title":"Usefulness of strontium-89 for bone pain palliation in metastatic breast cancer patients","volume":"21","author":"Fuster","year":"2000","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.radonc.2005.03.003_bib21","first-page":"585","article-title":"Bone pain palliation with 85Sr therapy","volume":"40","author":"Giammarile","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00000421-200002000-00023","article-title":"Preliminary results of the use of Re-186-HEDP for palliation of pain in patients with metastatic bone disease","volume":"23","author":"Giannakenas","year":"2000","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib23","first-page":"1150","article-title":"The placorhen study: a double-blind, placebo-controlled, randomized radionuclide study with 186Re-etidronate in hormone-resistant prostate cancer patients with painful bone metastases","volume":"43","author":"Han","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib24","first-page":"895","article-title":"Efficacy of rhenium-186-etidronate in breast cancer patients with metastatic bone pain [abstract]","volume":"24","author":"Han","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib25","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1007\/s002590050309","article-title":"The effect of repeated strontium-89 chloride therapy on bone pain palliation in patients with skeletal cancer metastases","volume":"25","author":"Kasalicky","year":"1998","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib26","first-page":"23","article-title":"The effect of 153Sm-EDTMP on painful bone metastases; comparison with 89SrCl [abstract]","author":"Kasalicky","year":"1996","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib27","first-page":"1689","article-title":"Evaluation of toxicity and efficacy of 186Re-hydroxyethylidene diphosphonate in patients with painful bone metastases of prostate or breast cancer","volume":"41","author":"Kolesnikov-Gauthier","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib28","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1007\/s002590000315","article-title":"Treatment of bone metastases of prostate cancer with strontium-89 chloride: efficacy in relation to the degree of bone involvement","volume":"27","author":"Kraeber-Bodere","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib29","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF02988205","article-title":"Palliative analgesic effect of Re-186 HEDP in various cancer patients with bone metastases","volume":"14","author":"Kucuk","year":"2000","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib30","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1259\/0007-1285-64-765-816","article-title":"Strontium-89 chloride for pain palliation in prostatic skeletal malignancy","volume":"64","author":"Laing","year":"1991","journal-title":"Br J Radiol"},{"key":"10.1016\/j.radonc.2005.03.003_bib31","first-page":"836","article-title":"Strontium-89 (Sr-89) in the palliative therapy of painful bone metastases: a phase II clinical study [abstract]","volume":"30","author":"Lamki","year":"1989","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib32","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/00000421-199604000-00003","article-title":"Strontium-89 chloride (Metastron) for palliative treatment of bony metastases. The University of Minnesota experience","volume":"19","author":"Lee","year":"1996","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib33","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/0277-5379(91)90257-E","article-title":"A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone","volume":"27","author":"Lewington","year":"1991","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2005.03.003_bib34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/sj.bjc.6601158","article-title":"Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases","volume":"89","author":"Liepe","year":"2003","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2005.03.003_bib35","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0090-4295(97)00326-9","article-title":"Painful bone metastases in hormone-refractory prostate cancer: economic costs of strontium-89 and\/or external radiotherapy","volume":"50","author":"Malmberg","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2005.03.003_bib36","first-page":"1877","article-title":"Rhenium-186(Sn)HEDP for treatment of painful osseous metastases: results of a double-blind crossover comparison with placebo","volume":"32","author":"Maxon","year":"1991","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/00006231-199407000-00002","article-title":"A retrospective analysis of the cost effectiveness of treatment with Metastron (89Sr-chloride) in patients with prostate cancer metastatic to bone","volume":"15","author":"McEwan","year":"1994","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.radonc.2005.03.003_bib38","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000475428","article-title":"A retrospective analysis of the cost effectiveness of treatment with Metastron in patients with prostate cancer metastatic to bone","volume":"26","author":"McEwan","year":"1994","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2005.03.003_bib39","first-page":"S44","article-title":"Strontium-89 to treat patients with breast cancer metastatic to bone [abstract]","volume":"21","author":"McEwan","year":"1994","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib40","first-page":"91","article-title":"An evaluation of the safety and efficacy of treatment with strontium-89 in patients who have previously received wide field radiotherapy","volume":"3","author":"McEwan","year":"1990","journal-title":"Antibod Immunoconj Radiopharm"},{"key":"10.1016\/j.radonc.2005.03.003_bib41","article-title":"Radiotherapy for the palliation of painful bone metastases [Cochrane Review]","author":"McQuay","year":"2000","journal-title":"The Cochrane Library"},{"key":"10.1016\/j.radonc.2005.03.003_bib42","first-page":"146P","article-title":"Efficacy and toxicity of 153Sm EDTMP in the palliative treatment of painful skeleton metastases: results of an IAEA international multicenter study [abstract]","volume":"51","author":"Olea","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0302-2838(03)00364-6","article-title":"Strontium89 chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European organisation for research and treatment of cancer genitourinary group","volume":"44","author":"Oosterhof","year":"2003","journal-title":"Eur Urol"},{"key":"10.1016\/j.radonc.2005.03.003_bib44","first-page":"160P","article-title":"188Re HEDP in the treatment of bone metastases generating from prostate cancer [abstract]","volume":"43","author":"Palmedo","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib45","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/00003072-199909000-00001","article-title":"Pain palliation with rhenium-186 HEDP in breast cancer patients with disseminated bone metastases","volume":"24","author":"Palmedo","year":"1999","journal-title":"Clin Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib46","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s002590050017","article-title":"Dose escalation study with rhenium-188 hydroxyethylidene diphosphonate in prostate cancer patients with osseous metastases","volume":"27","author":"Palmedo","year":"2000","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib47","doi-asserted-by":"crossref","first-page":"2869","DOI":"10.1200\/JCO.2003.12.060","article-title":"Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: randomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate","volume":"21","author":"Palmedo","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib48","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s002590050143","article-title":"Strontium-89 for palliation of pain from bone metastases in patients with prostate and breast cancer","volume":"24","author":"Pons","year":"1997","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib49","first-page":"38","article-title":"Strontium-89 as an adjuvant to external beam radiation improves pain relief and delays disease progression in advanced prostate cancer: results of a randomized controlled trial","volume":"20","author":"Porter","year":"1993","journal-title":"Semin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib50","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0167-8140(94)90411-1","article-title":"A comparison of the palliative effects of strontium-89 and external beam radiotherapy in metastatic prostate cancer","volume":"31","author":"Quilty","year":"1994","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib51","first-page":"1511","article-title":"Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain","volume":"37","author":"Quirijnen","year":"1996","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib52","first-page":"27","article-title":"Strontium 89 for palliation of bone metastases","volume":"78","author":"Reddy","year":"1986","journal-title":"J Natl Med Assoc"},{"key":"10.1016\/j.radonc.2005.03.003_bib53","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0959-8049(97)00155-X","article-title":"A dose-controlled study of 153Sm-ethylenediaminetetramethylenephosphonate (EDTMP) in the treatment of patients with painful bone metastases","volume":"33","author":"Resche","year":"1997","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.radonc.2005.03.003_bib54","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1148\/radiographics.9.2.2467331","article-title":"Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone","volume":"9","author":"Robinson","year":"1989","journal-title":"Radiographics"},{"key":"10.1016\/j.radonc.2005.03.003_bib55","first-page":"843","article-title":"Strontium-89: improved clinical response with increasing dose in patients with painful metastatic prostate and breast cancer in bone [abstract]","volume":"30","author":"Robinson","year":"1989","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib56","first-page":"133","article-title":"Efficacy and toxicity of intravenous strontium-89 for symptomatic osseous metastases","volume":"14","author":"Rogers","year":"1998","journal-title":"J Brachyther Int"},{"key":"10.1016\/j.radonc.2005.03.003_bib57","series-title":"Hemibody irradiation in radiation oncology technology and biology","author":"Rubin","year":"1994"},{"key":"10.1016\/j.radonc.2005.03.003_bib58","first-page":"321","article-title":"A double blind placebo controlled study of 153Samarium-EDTMP for palliation of bone pain in patients with hormone-refractory prostate cancer [abstract]","volume":"157","author":"Sartor","year":"1997","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2005.03.003_bib59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/0742-969X.1996.11882817","article-title":"Strontium-89 for symptomatic metastatic prostate cancer to bone: recommendations for hospice patients","volume":"11","author":"Schmeler","year":"1996","journal-title":"Hospice J"},{"key":"10.1016\/j.radonc.2005.03.003_bib60","doi-asserted-by":"crossref","first-page":"445","DOI":"10.3109\/00365599709030639","article-title":"Rhenium-186 HEDP: palliative radionuclide therapy of painful bone metastases. Preliminary results","volume":"31","author":"Schoeneich","year":"1997","journal-title":"Scand J Urol Nephrol"},{"key":"10.1016\/j.radonc.2005.03.003_bib61","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1010658522847","article-title":"Metastatic bone pain palliation with 89-Sr and 186-Re-HEDP in breast cancer patients","volume":"66","author":"Sciuto","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.radonc.2005.03.003_bib62","first-page":"79","article-title":"Effects of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer: a randomized clinical trial","volume":"43","author":"Sciuto","year":"2002","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib63","first-page":"647","article-title":"Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases","volume":"41","author":"Sciuto","year":"2000","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib64","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1200\/JCO.1998.16.4.1574","article-title":"Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial","volume":"16","author":"Serafini","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib65","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/00006231-199908000-00003","article-title":"Effective and economical option for pain palliation in prostate cancer with skeletal metastases: 32P therapy revisited","volume":"20","author":"Shah Syed","year":"1999","journal-title":"Nucl Med Commun"},{"key":"10.1016\/j.radonc.2005.03.003_bib66","first-page":"345","article-title":"Strontium-89 therapy for the pain of osseous metastases","volume":"26","author":"Silberstein","year":"1985","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib67","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S0360-3016(03)00274-8","article-title":"Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable: results of a double-blind randomized study","volume":"56","author":"Smeland","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2005.03.003_bib68","first-page":"65P","article-title":"Long-term analysis of clinical data from patients treated with SN-117M DTPA for metastatic bone pain [abstract]","volume":"40","author":"Srivastava","year":"1999","journal-title":"J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib69","first-page":"61","article-title":"Treatment of metastatic bone pain with tin-117m Stannic diethylenetriaminepentaacetic acid: a phase I\/II clinical study","volume":"4","author":"Srivastava","year":"1998","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.radonc.2005.03.003_bib70","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s002590050351","article-title":"Multicentre trial on the efficacy and toxicity of single-dose samarium-153-ethylene diamine tetramethylene phosphonate as a palliative treatment for painful skeletal metastases in China","volume":"26","author":"Tian","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.radonc.2005.03.003_bib71","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/S0140-6736(00)03639-4","article-title":"Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial","volume":"357","author":"Tu","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2005.03.003_bib72","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1078-1439(97)00013-6","article-title":"Strontium-89 combined with doxorubicin in the treatment of patients with androgen-independent prostate cancer","volume":"2","author":"Tu","year":"1996","journal-title":"Urol Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib73","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.1989.7.12.1926","article-title":"A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases","volume":"7","author":"Turner","year":"1989","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.radonc.2005.03.003_bib74","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1054\/bjoc.2000.1610","article-title":"Metastron users group. Less pain does equal better quality of life following strontium-89 therapy for metastatic prostate cancer","volume":"84","author":"Turner","year":"2001","journal-title":"Br J Cancer"},{"key":"10.1016\/j.radonc.2005.03.003_bib75","first-page":"219","article-title":"Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience","volume":"13","author":"Windsor","year":"2001","journal-title":"Clin Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814005001040?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167814005001040?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,19]],"date-time":"2019-02-19T18:33:20Z","timestamp":1550601200000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167814005001040"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,6]]},"references-count":75,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,6]]}},"alternative-id":["S0167814005001040"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2005.03.003","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2005,6]]}}}